SUBSCRIBE: Print / Digital / eNewsletter
"As clinicians for patients requiring cancer care, we need to ensure that we are optimizing all precautions for both the elderly and for those with potential immunosuppression," writes Neal D. Shore, MD.
“It hasn’t become the gold standard yet. There are still a lot of inter-reader reliability issues. The same MRI scans, read by different radiologists, may be read differently," says one urologist.
"Given that most urologic outpatient visits are non-urgent, almost all in-person visits should be eliminated out of appropriate concern for COVID-19," advise Drs. Gadzinski, Ellimoottil, Odisho, Watts, and Gore.
ImmunityBio announced that the FDA has granted Breakthrough Therapy designation for its interleukin-15 agonist complex, N-803, in combination with Bacillus Calmette-Guerin (BCG), for the treatment of patients with BCG-unresponsive nonmuscle-invasive bladder carcinoma in situ.
"We are using a 'cell phone' waiting room. When a patient arrives, they call our front desk. Then we text or call them when their exam room is ready," says one urologist.
Interim results from a clinical trial of a next-generation penile traction therapy device were encouraging and demonstrated statistically significant increases in penile length and a smaller reduction in erectile function among post-prostatectomy men who were treated with the device, known as RestoreX, according to PathRight Medical.
Nanospectra Biosciences, Inc. recently announced the start of a pivotal study to determine the efficacy of using magnetic resonance imaging/ultrasound fusion imaging technology to direct focal ablation of prostate tissue using nanoparticle-directed laser ablation.
The FDA has accepted for review Urovant Sciences’ New Drug Application for once-daily 75 mg vibegron for the treatment of patients with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Avoid making decisions motivated by emotion and fear, advises Jeff Witz, CFP.
Recent research shows contemporary imaging and biopsy techniques often fail to identify contralateral tumors in men presumed to have unilateral prostate cancer—and the results have significant implications for identifying candidates for hemiablation.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
